Theragenics to distribute Oncuras brachytherapy products

Theragenics has signed a non-exclusive agreement with Oncura to distribute its brachytherapy-related products in North America.

The one-year agreement is effective May 1 and provides for additional one-year terms upon mutual agreement of the parties, said the Buford, Ga.-based Theragenics.

Oncura, a unit of GE Healthcare, manufactures, markets and sells the iodine-125 based OncoSeed used in prostate cancer treatments.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.